Bolt Biotherapeutics, Inc. Financing Cash Flow
Bolt Biotherapeutics, Inc. (BOLT) reported Financing Cash Flow of $25.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $19.00K, a 35.71% increase year-over-year.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $6.00K.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.00K, a 82.76% decline year-over-year.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $19.00K, a 82.41% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $108.00K, a 57.31% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $253.00K, a 49.70% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $503.00K, a 99.84% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $25.00K 10-Q · filed 2026-08-11 | $30.00K derived: sum of 3 quarters · filed 2026-08-11 | $30.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $6.00K 10-Q · filed 2026-05-12 | $11.00K derived: sum of 2 quarters · filed 2026-05-12 | $11.00K derived: sum of 3 quarters · filed 2026-05-12 | $25.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.00K derived: sum of 2 quarters · filed 2026-03-12 | $19.00K derived: sum of 3 quarters · filed 2026-08-11 | $19.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $14.00K derived: sum of 2 quarters · filed 2026-08-11 | $14.00K 10-Q · filed 2025-11-12 | $43.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $14.00K 10-Q · filed 2026-08-11 | $43.00K derived: sum of 3 quarters · filed 2026-08-11 | $43.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $29.00K derived: sum of 2 quarters · filed 2026-05-12 | $29.00K derived: sum of 3 quarters · filed 2026-05-12 | $108.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $29.00K derived: sum of 2 quarters · filed 2026-03-12 | $108.00K derived: sum of 3 quarters · filed 2026-03-12 | $108.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $79.00K derived: sum of 2 quarters · filed 2025-11-12 | $79.00K 10-Q · filed 2025-11-12 | $185.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $79.00K 10-Q · filed 2025-08-14 | $185.00K derived: sum of 3 quarters · filed 2025-08-14 | $185.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $106.00K derived: sum of 2 quarters · filed 2025-05-12 | $106.00K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $106.00K derived: sum of 2 quarters · filed 2025-03-24 | $253.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $147.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $147.00K 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $144.00K derived: sum of 2 quarters · filed 2024-03-21 | $396.00K derived: sum of 3 quarters · filed 2024-03-21 | $503.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $252.00K derived: sum of 2 quarters · filed 2023-11-09 | $359.00K 10-Q · filed 2023-11-09 | $854.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $359.00K 10-Q · filed 2023-08-07 | $854.00K derived: sum of 3 quarters · filed 2023-08-07 | $1.04M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $107.00K 10-Q · filed 2023-05-11 | $602.00K derived: sum of 2 quarters · filed 2023-05-11 | $787.00K derived: sum of 3 quarters · filed 2023-05-11 | $14.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $680.00K derived: sum of 2 quarters · filed 2023-03-29 | $14.09M derived: sum of 3 quarters · filed 2023-03-29 | $311.11M 10-K · filed 2023-03-29 |
| 2021-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $13.59M derived: sum of 2 quarters · filed 2022-11-10 | $310.61M 10-Q · filed 2022-11-10 | $309.55M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $13.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $310.43M 10-Q · filed 2022-08-10 | $309.36M derived: sum of 3 quarters · filed 2022-08-10 | $308.44M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $297.02M 10-Q · filed 2022-05-12 | $295.95M derived: sum of 2 quarters · filed 2022-05-12 | $295.03M derived: sum of 3 quarters · filed 2022-05-12 | $336.58M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$1.99M derived: sum of 2 quarters · filed 2022-03-30 | $39.56M derived: sum of 3 quarters · filed 2022-03-30 | $39.60M 10-K · filed 2022-03-30 |
| 2020-09-30 | -$923.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $40.63M derived: sum of 2 quarters · filed 2021-11-09 | $40.66M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $41.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $41.59M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $34.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |